Overview

InFocus Therapeutics develops precision-designed RNA-targeting molecular glues to restore gene function in hard-to-treat diseases. Our proprietary, chemistry-aware generative AI platform delivers potent, selective compounds with reduced toxicity – achieving a 40% hit rate and 2 lead candidates in just 4 months. Backed by global drug hunters from the first-wave of AI Drug Discovery companies, we’re building the next generation of RNA-targeted therapies.